Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 258Carcinoma, Non-Small-Cell Lung 226Carcinoma, Renal Cell 143Neoplasm Metastasis 97Neoplasms 93Carcinoma, Hepatocellular 85Squamous Cell Carcinoma of Head and Neck 84Colorectal Neoplasms 81Lung Neoplasms 73Stomach Neoplasms 56Pancreatic Neoplasms 56Carcinoma, Transitional Cell 49Hodgkin Disease 47Urinary Bladder Neoplasms 42Breast Neoplasms 40Ovarian Neoplasms 37Head and Neck Neoplasms 37Triple Negative Breast Neoplasms 34Small Cell Lung Carcinoma 33Sarcoma 32Prostatic Neoplasms 32Glioblastoma 32Brain Neoplasms 32Recurrence 27Kidney Neoplasms 27Multiple Myeloma 25Uveal Melanoma 23Esophageal Neoplasms 23Uterine Cervical Neoplasms 22Skin Neoplasms 22

Interventions

pembrolizumab 2enfortumab vedotin 2Gemcitabine 2Carboplatin 2zimberelimab 1sirtratumab vedotin 1sacituzumab govitecan 1olaparib 1avelumab 1Oxaliplatin 1Nivolumab 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Metastatic Urothelial Cancer × Nivolumab × Clear all
NCT03451331 2024-05-16

Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer

Hoosier Cancer Research Network

Phase 2 Completed
49 enrolled 15 charts
Genitourinary

Metastatic Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡